This cancer drug stock could double as its treatment hits the market, JPMorgan says
分析失败
The investment bank initiated coverage with an overweight rating.
LISA · 延伸对话
与 Lisa 深入探讨这篇报告
基于本报告上下文的延伸分析
The investment bank initiated coverage with an overweight rating.
基于本报告上下文的延伸分析